AI and the Pharmaceutical Industry — 2026-09-18 (Fri)

Overview

Today's biggest focus is the Novo Nordisk–Anthropic partnership. Multiple outlets reported on a drug discovery R&D collaboration centered on Claude Science, making visible a major pharmaceutical company partnering directly with an LLM company. In parallel, ByteDance-affiliated AI drug discovery subsidiary Anew Labs secured $290 million (roughly ¥45 billion) in its first funding round, reaching a $1.5 billion valuation, and a leading synthetic biology company signaled an expected doubling of orders. It was a day marked by simultaneous capital inflows into AI drug discovery from both Chinese players and Western pharmaceutical majors.

By Category

In drug discovery, three distinct threads emerged in parallel: the ByteDance-originated Anew Labs funding round, the Novo Nordisk×Anthropic partnership, and Singapore-based ChemLex raising $45 million to launch an autonomous lab. This amounts to three patterns surfacing on the same day — a spun-off subsidiary raising external capital, an established pharmaceutical major partnering with an LLM company, and a startup securing independent funding. The synthetic biology leader's projected order doubling (to $100 million next year) was also reported as evidence backing demand for AI drug discovery.

In the enterprise AI infrastructure and governance category, Tempus AI continued its share price rally on strong earnings plus a $1.5 billion contract, while Cognita Imaging won a $1.29 million FDA contract for evaluating generative AI in radiology. The Novo Nordisk×Anthropic partnership was also covered under this category, reflecting overlap between regulatory contract wins and major pharma AI infrastructure investment happening simultaneously.

Reading the Investment Map

The largest figure by far is Anew Labs' $1.5 billion valuation (on a $290 million raise), underscoring a concentration of capital in Chinese-origin AI drug discovery startups. Next comes Tempus AI's $1.5 billion contract, followed by ChemLex's $45 million raise. On the government funding side, Cognita Imaging's $1.29 million FDA contract is modest in scale but represents public investment in the regulatory-compliance space. Overall, the pattern shows private venture capital flowing toward drug discovery platforms (Anew Labs, ChemLex), while public and contract-based funding flows toward validating clinical applications (Tempus, Cognita).

What to Watch

- Whether Anew Labs' funding round continues to ripple through AI drug discovery stocks broadly. - Whether further reporting emerges on concrete progress in the Novo Nordisk×Anthropic partnership.